Skip to content

Internet Buzzing About FDA Advisory Committee Recommendation For Approval Of Aegerion Pharmaceuticals’ Orphan Drug Lomitapide

October 17, 2012

       On October 17, 2012, Aegerion Pharmaceuticals announces that the FDA Endocrinologic and Metabolic Drugs Advisory Committee (EMDAC) by a vote of 13 to 2, that orphan drug Lomitapide is presented with sufficient safety and efficacy data to support its marketing. Lomitapide is for the treatment of Homozygous Familial Hypercholesterolemia (HoFH) when used as an adjunct to a low-fat diet and other lipid-lowering therapies. The FDA does not have to follow the recommendation.  Lomitapide has a December 29, 2012, PDUFA date

        The Internet is Buzzing : 

1)  Bloomberg BusinessWeek.com October 17, 2012 article titled,”Aegerion Drug Wins Panel Support for Cholesterol Disease”  

2)  Forbes.com October 17, 2012 article titled,”FDA Reviewers Recommend Approval for Lomitapide for Homozygous Familial Hypercholesterolemia”  

3)  TheStreet.com October 17, 2012 article titled,”Aegerion Pharma FDA Panel Live Blog”  

Copyright  © 2012-2013, Ann-Teresa Cusenza and Orphan Druganaut Blog.  All rights reserved.

Advertisements
Leave a Comment

Leave a Reply

Fill in your details below or click an icon to log in:

WordPress.com Logo

You are commenting using your WordPress.com account. Log Out / Change )

Twitter picture

You are commenting using your Twitter account. Log Out / Change )

Facebook photo

You are commenting using your Facebook account. Log Out / Change )

Google+ photo

You are commenting using your Google+ account. Log Out / Change )

Connecting to %s

%d bloggers like this: